10.07 USD
▼-0.53-5.00%
盘后 12.88 0.00%
2026-09-15
市值
$611.76M
市盈率
—
EPS
-1.72
股息率
—
52 周区间
10.00 – 34.48
成交量
159.31K
Beta
0.23
目标价
36.04
52W 低 10.0052W 高 34.48
价格走势
公司简介
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological da...